Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 1, pp 16–25 | Cite as

Risk factors for QTc-prolongation: systematic review of the evidence

  • Eline Vandael
  • Bert Vandenberk
  • Joris Vandenberghe
  • Rik Willems
  • Veerle Foulon
Review Article

Abstract

Background QTc-interval prolongation has been associated with serious adverse events, such as Torsade de Pointes and sudden cardiac death. In the prevention of QTc-prolongation, special attention should go to high-risk patients. Aim of the review The aim of this review is to summarize and assess the evidence for different risk factors for QTc-prolongation (demographic factors, comorbidities, electrolytes, QTc-prolonging medication). Methods Potential studies were retrieved based on a systematic search of articles published until June 2015 in the databases Medline and Embase. Both terms about QTc-prolongation/Torsade de Pointes and risk factors were added in the search strategy. The following inclusion criteria were applied: randomized controlled trials and observational studies; inclusion of ≥500 patients from a general population (not limited to specific disease states); assessment of association between QTc-interval and risk factors. For the articles that met the inclusion criteria, the following data were extracted: study design, setting and study population, number of patients and cases of QTc-prolongation, method of electrocardiogram-monitoring, QTc-correction formula, definition of QTc-prolongation, statistical methods and results. Quality assessment was performed using the GRADE approach (for randomized controlled trials) and the STROBE-recommendations (for observational studies). Based on the number of significant results and the level of significance, a quotation of the evidence was allocated. Results Ten observational studies could be included, with a total of 89,532 patients [prospective cohort design: N = 6; multiple regression analyses: N = 5; median STROBE score = 17/22 (range 15–18)]. Very strong evidence was found for hypokalemia, use of diuretics, antiarrhythmic drugs and QTc-prolonging drugs of list 1 of CredibleMeds. Little or no evidence was found for hyperlipidemia, the use of digoxin or statins, neurological disorders, diabetes, renal failure, depression, alcohol abuse, heart rate, pulmonary disorders, hormone replacement therapy, hypomagnesemia, history of a prolonged QTc-interval/Torsade de Pointes, familial history of cardiovascular disease, and the use of only QTc-prolonging drugs of list 2 or 3 of CredibleMeds. Conclusion This systematic review gives a clear overview of the available evidence for a broad range of risk factors for QTc-prolongation.

Keywords

QTc-prolongation Risk factors Sudden cardiac death Systematic review Torsade de Pointes 

Notes

Funding

Ph.D. student E.V. is supported by funding of the Belgian government agency for Innovation by Science and Technology (IWT). R.W. is supported as a clinical researcher by the Fund for Scientific Research Flanders.

Conflicts of interest

None.

Supplementary material

11096_2016_414_MOESM1_ESM.doc (298 kb)
Supplementary material 1 (DOC 299 kb)

References

  1. 1.
    Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934–47.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70:16–23.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bazett HC. An analysis of the time-relations of the electrocardiograms. Heart. 1920;7:353–70.Google Scholar
  4. 4.
    Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001;12:411–20.CrossRefPubMedGoogle Scholar
  5. 5.
    Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2009;53:982–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Vandenberk B, Vandael E, Spriet I, Garweg C, Vandenberghe J, Van Den Bosch B, et al. Which QT correction formulae to use for QT monitoring? J Am Heart Assoc. 2016;. doi: 10.1161/JAHA.116.003264.PubMedPubMedCentralGoogle Scholar
  7. 7.
    CPMP/986/96. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London: Committee for Proprietary Medicinal Products; 1997.Google Scholar
  8. 8.
    Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3:241–53.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    U.S. Department of Health and Human Services. Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.Google Scholar
  10. 10.
    Woosley RL, Romero KA. QTdrugs List, December 2015, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755. www.crediblemeds.org. Accessed 12 April 2016.
  11. 11.
    European Medicines Agency (EMA): Restrictions on the use of domperidone-containing medicines, EMA/465179/2014. http://www.ema.europa.eu. Accessed 4 April 2016.
  12. 12.
    Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013;54:1–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Schachtele S, Tumena T, Gassmann KG, Fromm MF, Maas R. Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients. Dtsch Arztebl Int. 2014;111:255–63.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, et al. Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group. Encephale. 2002;28:552–62.PubMedGoogle Scholar
  16. 16.
    Royal College of Psychiatrists L. Consensus statement on high-dose antipsychotic medication. 2005.Google Scholar
  17. 17.
    Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc. 2013;88:315–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.CrossRefGoogle Scholar
  21. 21.
    Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: third national health and nutrition examination survey. Eur J Cardiovasc Prev Rehabil. 2005;12:363–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Grandinetti A, Seifried S, Mor J, Chang HK, Theriault AG. Prevalence and risk factors for prolonged QTc in a multiethnic cohort in rural Hawaii. Clin Biochem. 2005;38:116–22.CrossRefPubMedGoogle Scholar
  23. 23.
    Sohaib SMA, Papacosta O, Morris RW, Macfarlane PW, Whincup PH. Length of the QT interval: determinants and prognostic implications in a population-based prospective study of older men. J Electrocardiol. 2008;41:704–10.CrossRefPubMedGoogle Scholar
  24. 24.
    Akylbekova EL, Crow RS, Johnson WD, Buxbaum SG, Njemanze S, Fox E, et al. Clinical correlates and heritability of QT interval duration in blacks the Jackson Heart Study. Circ Arrhythm Electrophysiol. 2009;2:427–32.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Pasquier M, Pantet O, Hugli O, Pruvot E, Buclin T, Waeber G, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J. 2012;42:933–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Pickham D, Helfenbein E, Shinn JA, Chan G, Funk M, Weinacker A, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Crit Care Med. 2012;40:394–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Soliman EZ, Howard G, Cushman M, Kissela B, Kleindorfer D, Le Anh MS, et al. Prolongation of QTc and risk of stroke: the REGARDS (REasons for Geographic and Racial Differences in Stroke) Study. J Am Coll Cardiol. 2012;59:1460–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479–87.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Jardin CGM, Putney D, Michaud S. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents. Ann Pharmacother. 2014;48:196–202.CrossRefPubMedGoogle Scholar
  31. 31.
    Ponte ML, Keller GA, Di Girolamo G. Mechanisms of drug induced QT interval prolongation. Curr Drug Saf. 2010;5:44–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Digby GC, Perez Riera AR, Barbosa BR, Simpson CS, Redfearn DP, Methot M, et al. Acquired long QT interval: a case series of multifactorial QT prolongation. Clin Cardiol. 2011;34:577–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG screening outcome in psychiatry study. Am J Psychiat. 2013;170:1468–76.CrossRefPubMedGoogle Scholar
  34. 34.
    Woosley RL, Romero K. Assessing cardiovascular drug safety for clinical decision-making. Nat Rev Cardiol. 2013;10:330–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Department of Pharmaceutical and Pharmacological SciencesKU LeuvenLeuvenBelgium
  2. 2.Department of Cardiovascular SciencesKU LeuvenLeuvenBelgium
  3. 3.Department of CardiologyUniversity Hospitals LeuvenLeuvenBelgium
  4. 4.Department of NeurosciencesKU LeuvenLeuvenBelgium
  5. 5.Department of PsychiatryUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations